Safety and efficacy of CpG-containing oligodeoxynucleotides as immunological adjuvants in rabbits

Vaccine

Volumn 21, Issue 27-30, 2003, Pages 4368-4372

  Ioannou, X P ^a   Gomis, S M ^a   Hecker, R ^b   Babiuk, L A ^a   Van Drunen Littel van Den Hurk, S ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b QIAGEN GMBH   (Germany)

Author keywords

Adjuvant; CpG ODN; Rabbits

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; DINUCLEOTIDE; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYNUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; EMULSION; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0348078306     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00437-7     Document Type: Article

References (15)

1. Broderson JR. A retrospective review of lesions associated with the use of Freund's adjuvant. Lab Anim Sci 1989;39:400-5.
2. Cox J.C., Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine. 15:1997;248-256.
3. Bomford R. Aluminium salts: perspectives in their use as adjuvants. In: Gregoriadis G, Allison AC, Poste G, editors. Immunological adjuvants and vaccines. New York: Plenum Press; 1989. p. 35-41.
4. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 18:2000;1755-1762.
5. Davis H.L., Weeratna R.D., Waldschmidt M., Tygrett L., Schorr J., Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:1998;870-876.
6. Klinman D.M., Barnhart K.M., Conover J. CpG motifs as immune adjuvants. Vaccine. 17:1999;19-25.
7. Davis HL, Krieg AM, Cooper CL, Morris ML, Cameron DW, Heathcote J. CpG ODN is generally well tolerated and highly effective in humans as adjuvant to HBV vaccine: preliminary results of phase 1 trial with CpG ODN 7909. In: Proceedings of the Second International Symposium on Activating Immunity with CpG Oligos, Amelia Island, FL, 2001 [abstract].
8. Rankin R., Pontarollo R., Ioannou X.et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense. Nucleic Acid Drug Dev. 11:2001;333-340.
9. van Drunen Littel-van den Hurk S., Gifford G.A., Babiuk L.A. Epitope specificity of the protective immune response induced by individual bovine herpesvirus-1 glycoproteins. Vaccine. 8:1990;358-368.
10. Trudel M., Nadon F., Seguin C., Dionne G., Lacroix M. Identification of a synthetic peptide as part of a major neutralization epitope of respiratory syncytial virus. J. Gen. Virol. 68:1987;2273-2280.
11. Schaaper W.M., Lankhof H., Puijk W.C., Meloen R.H. Manipulation of antipeptide immune response by varying the coupling of the peptide with the carrier protein. Mol. Immunol. 26:1989;81-85.
12. Samani T.D., Jolles B., Laigle A. Best minimally modified antisense oligonucleotides according to cell nuclease activity. Antisense. Nucleic Acid Drug Dev. 11:2001;129-136.
13. van Drunen Littel-van den Hurk S., Van Donkersgoed J., Kowalski J.et al. A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle. Vaccine. 12:1994;1295-1302.
14. Ioannou X.P., Griebel P., Hecker R., Babiuk L.A., van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus-1 glycoprotein D plus emulsigen are increased by formulation with CpG oligodeoxynucleotides. J. Virol. 76:2002;9002-9010.
15. Ioannou X.P., Gomis S.M., Karvonen B., Hecker R., Babiuk L.A., van Drunen Littel-van den Hurk S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and changes the bias of the immune responses to a herpesvirus glycoprotein. Vaccine. 3359:2002;1-11.